Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
31-45 of 2360 results
MedImmune completes out-licensing deal with Allergan for MEDI2070
AstraZeneca's global biologics research and development arm, MedImmune has completed out-licensing agreement with Allergan for the global rights to MEDI2070.
Contract Research & Services > Contract Services > News
Grünenthal acquires US-based Thar Pharmaceuticals
Germany-based Grünenthal has acquired US clinical-stage, specialty pharmaceutical firm Thar Pharmaceuticals.
Contract Research & Services > Contract Services > News
Bristol-Myers, Infinity partner for Opdivo- IPI-549 combo trial in advanced solid tumors
By PBR Staff Writer
Bristol-Myers Squibb is evaluating its Opdivo (nivolumab) cancer drug in combination with Infinity Pharmaceuticals’ IPI-549 immuno-oncology development candidate in patients with advanced solid tumors.
Contract Research & Services > Contract Services > News
Lexicon acquires rights to neuropathic pain candidate developed with BMS
Lexicon Pharmaceuticals has obtained exclusive research, development and commercialization rights to LX9211 (BMS-986176), a development candidate for neuropathic pain that was jointly developed by Lexicon and Bristol-Myers Squibb (BMS) as part of their neuroscience drug discovery alliance.
Contract Research & Services > Contract Services > News
EnBiotix purchases AMP Therapeutics' anti-microbial peptide portfolio
EnBiotix has completed an asset acquisition of AMP Therapeutics (AMPT), an anti-microbial peptide portfolio firm of Boehringer Ingelheim Venture Fund and Novartis Venture Fund.
Contract Research & Services > Contract Services > News
Medivir agrees to buy two clinical stage oncology programs from Tetralogic
Medivir has agreed to acquire two clinical stage oncology programs from Tetralogic Pharmaceuticals, advancing and expanding its clinical pipeline.
Contract Research & Services > Contract Services > News
Aralez acquires US rights to AstraZeneca high blood pressure drug Toprol-XL
By PBR Staff Writer
Aralez Pharmaceuticals Trading DAC (Aralez Ireland) has acquired the US rights to AstraZeneca’s generic high blood pressure drug Toprol-XL.
Contract Research & Services > Contract Services > News
Catalyst receives SPA from the FDA for second phase 3 trial assessing firdapse to treat LEMS
Catalyst Pharmaceuticals has reached an agreement with the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the protocol design, clinical endpoints, and statistical analysis approach to be taken in its upcoming Phase 3 study assessing Firdapse (amifampridine phosphate) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Contract Research & Services > Contract Services > News
Dr Reddy's partners with Gland Pharma to market 8 ANDAs in US
Dr. Reddy’s Laboratories has partnered with Gland Pharma to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs).
Contract Research & Services > Contract Services > News
Zucara signs licensing deal with CDRD for therapeutic drug candidate
Zucara Therapeutics has signed a licensing agreement with the Centre for Drug Research and Development (CDRD) for access to a patented set of therapeutic drug compounds that will define its lead drug candidate.
Contract Research & Services > Contract Services > News
AstraZeneca to sell ex-US rights to Rhinocort Aqua nasal spray to J&J affiliate
By PBR Staff Writer
AstraZeneca has agreed to sell the rights outside the US for Rhinocort Aqua nasal spray to Johnson & Johnson’s affiliate Cilag GmbH International for $330m.
Contract Research & Services > Contract Services > News
Flamel Technologies signs deal with FDA on protocol for phase III trial of FT218
Flamel Technologies' Irish subsidiary, Flamel Ireland Holdings, has reached agreement with the US Food and Drug Administration (FDA) for the design and planned analysis of a Phase III clinical trial of FT218, a once nightly formulation of sodium oxybate utilizing the Company's proprietary drug delivery platform, Micropump.
Contract Research & Services > Contract Services > News
Insmed signs worldwide license deal with AstraZeneca for oral DPP1 inhibitor
Insmed has signed a licensing agreement with AstraZeneca for global exclusive rights to AZD7986, a novel oral inhibitor of dipeptidyl peptidase I (DPP1, also known as cathepsin C).
Contract Research & Services > Contract Services > News
Sarepta and Summit partner to develop novel therapies for Duchenne muscular dystrophy
Sarepta Therapeutics has entered into an exclusive licence agreement with Summit Therapeutics to develop drugs to treat Duchenne muscular dystrophy (DMD).
Contract Research & Services > Contract Services > News
Allergan signs $1.5bn licensing deal for AstraZeneca’s inflammatory diseases drug
By PBR Staff Writer
Allergan could pay as much as $1.52bn to MedImmune, the global biologics research and development arm of AstraZeneca, for the worldwide rights to an inflammatory diseases drug.
Contract Research & Services > Contract Services > News
31-45 of 2360 results